As of 12:24 PM on day 1, the IPO saw 2.82 times subscription in the retail category, and 1.45 times in the non-institutional investor (NII) category, while the portion reserved for qualified institutional buyers (QIBs) drew no bids.
GMP
In the unlisted market, Influx Healthtech’s grey market premium (GMP) stood at Rs 42 as of 11:54 AM Wednesday, indicating an estimated listing price of Rs 138, a 43.75% premium over the issue’s upper price band of Rs 96 per share.
The IPO, which opened for subscription today and will close on June 20, is being offered in a price band of Rs 91–96 per share. The minimum bid size is 1,200 shares.
Business overview and fund use
Mumbai-based Influx Healthtech is a contract development and manufacturing organisation (CDMO) that provides third-party product development and manufacturing services across nutraceuticals, cosmetics, ayurvedic products, and veterinary feed supplements.
The company operates from facilities in Thane, producing a wide array of products including tablets, gummies, jellies, skincare, and ayurvedic solutions.
Of the Rs 55.63 crore IPO, Rs 45.07 crore is a fresh issue, while Rs 10.56 crore is an offer-for-sale. The proceeds will be deployed primarily for setting up two new manufacturing units in the nutraceutical and veterinary segments at a cost of Rs 34.19 crore, besides funding machinery purchases and general corporate expenses.Influx Healthtech reported a revenue of Rs 104.99 crore and a net profit of Rs 13.37 crore in FY25.The shares are proposed to be listed on the NSE SME platform, with a tentative listing date of June 25.
Also read | Oswal Pumps IPO allotment to be finalised today. Check status, GMP and other details
(Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of Economic Times)
By
